CARB-X awards Day Zero Diagnostics $6.2M

CARB-X will support US-based Day Zero Diagnostics with $6.2M. The company combines whole-genome sequencing and machine learning to identify a pathogen and its drug-resistance profile within hours, not days.

CARB-X is awarding Day Zero Diagnostics, based in Boston, up to US$6.2 million in non-dilutive funding to develop a diagnostic system that could diagnose bacterial infections more quickly – within hours rather than days – and show physicians which antibiotics are most likely to effectively treat the infection. The innovative technology combines whole-genome sequencing and machine learning to identify the species of a pathogen and its drug-resistance profile without the need for culture, providing physicians with vital information to speed the appropriate treatment of serious drug-resistant bacterial infections in hours rather than days.

Read more: https://carb-x.org/carb-x-news/carb-x-awards-day-zero-diagnostics-6-2m-to-develop-a-new-test-that-would-diagnose-deadly-superbug-infections-faster-and-determine-what-antibiotic-would-be-most-effective/